Back to Journals » Drug Design, Development and Therapy » Volume 9

The role of taxanes in triple-negative breast cancer: literature review

Authors Mustacchi G, De Laurentiis M

Received 5 April 2015

Accepted for publication 16 June 2015

Published 5 August 2015 Volume 2015:9 Pages 4303—4318


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Professor Shu-Feng Zhou

Giorgio Mustacchi,1 Michelino De Laurentiis2

1Medical Oncology, University of Trieste, Trieste, 2Breast Medical Oncology Unit, National Cancer Institute, Fondazione G. Pascale, Napoli, Italy

Abstract: Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.

Keywords: nab-paclitaxel, paclitaxel, docetaxel, bevacizumab

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]